S1418/BR006 A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.

Brief description of study

If you have been diagnosed with triple negative breast cancer (TNBC) you may qualify to participate in a clinical trial investigating the investigational drug MK-3475.  The main purpose of this study is to see if immunotherapy with MK-3475 (pembrolizumab) can lower the risk of recurrence in patients with triple negative breast cancer who have residual cancer identified in the surgical specimen after standard chemotherapy.

Clinical Study Identifier: s16-02231
ClinicalTrials.gov Identifier: NCT02954874
Principal Investigator: Sylvia Adams.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.